Uterine leiomyoma, benign monoclonal tumors, afflict an estimated 60% of reproductive-aged women, with higher rates among African American women. Leiomyoma are associated with significant medical costs, impaired fertility potential, obstetric complications, and gynecologic morbidity. Currently, the effective clinical management of leiomyoma is limited by the fact that hysterectomy is the only cure. The purpose of this article is to provide the practitioner with a practical overview of the clinical management of this disease.
Keywords: Clinical management; Fibroids; Leiomyoma; Pathophysiology; Research.
Published by Elsevier Inc.